p53 Mutations in Human Cancers
Monica C. Hollstein, David Sidransky, Bert Vogelstein, Curtis C. Harris
Science · 1991 · 8,007 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Hollstein, M. C., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991). p53 mutations in human cancers. Science, 253(5015), 49–53. https://doi.org/10.1126/science.1905840
In text: (Hollstein et al., 1991)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. Analysis of these mutations can provide clues to the etiology of these diverse tumors and to the function of specific regions of p53. Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A transversions are the most frequent substitutions observed in cancers of the lung and liver. Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, and esophageal carcinomas are dispersed among numerous codons. In liver tumors in persons from geographic areas in which both aflatoxin B1 and hepatitis B virus are cancer risk factors, most mutations are at one nucleotide pair of codon 249. These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis.
Related papers
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary2021
- Hallmarks of Cancer: New Dimensions2022
- Comprehensive molecular characterization of human colon and rectal cancer2012
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer2015
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF12010
Metadata from OpenAlex (CC0). Citations are generated from the published record.